Peripheral Arterial Disease Trial, Recruiting NCT02795052 Sponsor: MD Stem Cells Condition: Peripheral Arterial Disease
Back to Peripheral Arterial Disease

Peripheral Arterial Disease Trial, Recruiting

NCT02795052
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have confirmed, lasting damage to your central or peripheral nervous system that is unlikely to get better with current standard treatments.
  • Your condition began at least 6 months ago.
  • If you are currently on medication or have had surgery for your condition, your health has been stable on that treatment and the treatment is not expected to reverse your nerve damage.
  • The trial doctors believe you could potentially improve with this stem cell treatment and that the procedure poses minimal risk to you.
  • You are over 18 years old and able to make your own informed decision about joining the trial.
  • You are in good enough general health that your primary care doctor can confirm you can safely undergo the procedure without significant health risks.

Who may not be able to join:

  • People who are not able to cooperate with or participate in a full neurological examination and evaluation.
  • People who are unwilling or unable to attend follow-up neurological appointments after the procedure.
  • People who are not able to give informed consent on their own.
  • People where the trial doctor believes the stem cell collection or treatment could pose a significant risk to their general health or nerve function.
  • People who are not medically stable or who may face serious health risks from undergoing the procedure.
  • Women who are pregnant at the time of treatment, or who are not willing to avoid becoming pregnant for 3 months after treatment.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Steven Levy, MD, MD Stem Cells

Phone: 203-423-9494

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
MD Stem Cells
Registry
ClinicalTrials.gov
Start date
1 June 2016
Est. completion
31 July 2027

Where this trial is recruiting

🇦🇪 United Arab Emirates 🇺🇸 United States

Primary endpoints

Change in Neurologic Function

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov